GlaxoSmithKline PLC said Thursday that it has kicked off a trial as part of its Phase 3 clinical program to test a treatment for severe eosinophilic asthma.
The trial, named SWIFT-2, is for an investigational medicine called GSK'294, a monoclonal antibody which is meant to suppress the protein responsible for the spread of eosinophils, a type of white blood cell involved in severe asthma.
The medicine is delivered as a subcutaneous injection every six months, GSK said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.